Burden of hepatitis E virus infection in pregnancy and maternofoetal outcomes: a systematic review and meta-analysis.
Adult
Case-Control Studies
Cohort Studies
Cross-Sectional Studies
Female
Hepatitis E
/ epidemiology
Hepatitis E virus
Humans
Infant, Low Birth Weight
Infant, Newborn
Infectious Disease Transmission, Vertical
Pregnancy
Pregnancy Complications, Infectious
/ epidemiology
Pregnancy Outcome
/ epidemiology
Seroepidemiologic Studies
Hepatitis E
Intrauterine deaths
Low birth weight
Maternal deaths
Miscarriage
Pregnancy
Preterm
Small for gestational age
Vertical transmission
Women health
Journal
BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799
Informations de publication
Date de publication:
28 Jul 2020
28 Jul 2020
Historique:
received:
13
08
2019
accepted:
16
07
2020
entrez:
30
7
2020
pubmed:
30
7
2020
medline:
18
5
2021
Statut:
epublish
Résumé
There is still a dearth of knowledge on the burden of HEV infection in the global population of pregnant women. Therefore, we conducted a systematic review and meta-analysis to estimate the global burden of HEV infection in pregnancy. We searched PubMed, Embase, Web of Knowledge, and Global Index Medicus to identify articles published until January 26, 2020. We considered cross-sectional, case-control, and cohort studies reporting the immunoglobulins M HEV seroprevalence in asymptomatic and symptomatic (jaundice or elevated transaminases) pregnant women or investigating the association between HEV infection and maternofoetal outcomes. We used a random-effects model to pool studies. This review was registered with PROSPERO, CRD42018093820. For HEV prevalence estimates, we included 52 studies (11,663 pregnant women). The seroprevalence was 3.5% (95% confidence interval: 1.4-6.4) in asymptomatic women (most of whom from high endemic areas). The prevalence in symptomatic women was 49.6% (42.6-56.7) with data only from HEV high endemic countries. In the multivariable meta-regression model, the prevalence was higher in symptomatic women compared to asymptomatic (adjusted prevalence odds ratio [aPOR]: 1.76; 95%CI: 1.61-1.91) and decreased with increasing year of publication (by 10-year) (aPOR: 0.90; 95%CI: 0.84-0.96). The proportion of HEV vertical transmission was 36.9% (13.3-64.2). Risk of bias was low, moderate and high respectively in 12 (23%), 37 (70%), and 4 studies (7%) addressing HEV prevalence estimation. HEV infection was associated with maternal deaths (pooled OR 7.17; 3.32-15.47), low birth weight (OR: 3.23; 1.71-6.10), small for gestational age (OR: 3.63; 1.25-10.49), preterm < 32 weeks (OR: 4.18; 1.23-14.20), and preterm < 37 weeks (OR: 3.45; 2.32-5.13), stillbirth (OR: 2.61; 1.64-4.14), intrauterine deaths (OR: 3.07; 2.13-4.43), and not with miscarriage (OR: 1.74; 0.77-3.90). All studies which assessed the association between HEV infection and maternofoetal outcomes had a moderate risk of bias. Findings from this study are suggestive of a high burden of HEV infection in pregnancy in high endemic countries, its association with poor maternofoetal outcomes, and a high rate of vertical transmission. This study supports the need for specific strategies to prevent exposure of pregnant women to HEV infection, especially in high endemic areas.
Sections du résumé
BACKGROUND
BACKGROUND
There is still a dearth of knowledge on the burden of HEV infection in the global population of pregnant women. Therefore, we conducted a systematic review and meta-analysis to estimate the global burden of HEV infection in pregnancy.
METHODS
METHODS
We searched PubMed, Embase, Web of Knowledge, and Global Index Medicus to identify articles published until January 26, 2020. We considered cross-sectional, case-control, and cohort studies reporting the immunoglobulins M HEV seroprevalence in asymptomatic and symptomatic (jaundice or elevated transaminases) pregnant women or investigating the association between HEV infection and maternofoetal outcomes. We used a random-effects model to pool studies. This review was registered with PROSPERO, CRD42018093820.
RESULTS
RESULTS
For HEV prevalence estimates, we included 52 studies (11,663 pregnant women). The seroprevalence was 3.5% (95% confidence interval: 1.4-6.4) in asymptomatic women (most of whom from high endemic areas). The prevalence in symptomatic women was 49.6% (42.6-56.7) with data only from HEV high endemic countries. In the multivariable meta-regression model, the prevalence was higher in symptomatic women compared to asymptomatic (adjusted prevalence odds ratio [aPOR]: 1.76; 95%CI: 1.61-1.91) and decreased with increasing year of publication (by 10-year) (aPOR: 0.90; 95%CI: 0.84-0.96). The proportion of HEV vertical transmission was 36.9% (13.3-64.2). Risk of bias was low, moderate and high respectively in 12 (23%), 37 (70%), and 4 studies (7%) addressing HEV prevalence estimation. HEV infection was associated with maternal deaths (pooled OR 7.17; 3.32-15.47), low birth weight (OR: 3.23; 1.71-6.10), small for gestational age (OR: 3.63; 1.25-10.49), preterm < 32 weeks (OR: 4.18; 1.23-14.20), and preterm < 37 weeks (OR: 3.45; 2.32-5.13), stillbirth (OR: 2.61; 1.64-4.14), intrauterine deaths (OR: 3.07; 2.13-4.43), and not with miscarriage (OR: 1.74; 0.77-3.90). All studies which assessed the association between HEV infection and maternofoetal outcomes had a moderate risk of bias.
CONCLUSIONS
CONCLUSIONS
Findings from this study are suggestive of a high burden of HEV infection in pregnancy in high endemic countries, its association with poor maternofoetal outcomes, and a high rate of vertical transmission. This study supports the need for specific strategies to prevent exposure of pregnant women to HEV infection, especially in high endemic areas.
Identifiants
pubmed: 32723309
doi: 10.1186/s12884-020-03116-2
pii: 10.1186/s12884-020-03116-2
pmc: PMC7388479
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
426Références
J Hepatol. 1996 Jul;25(1):20-7
pubmed: 8836897
J Gastroenterol Hepatol. 2007 May;22(5):676-82
pubmed: 17444855
Indian J Gastroenterol. 2016 Nov;35(6):450-458
pubmed: 27796940
Indian J Pediatr. 2003 Jan;70(1):37-9
pubmed: 12619951
Pathol Biol (Paris). 2011 Oct;59(5):e115-8
pubmed: 19896306
Diagn Microbiol Infect Dis. 2011 Oct;71(2):110-7
pubmed: 21868185
PLoS One. 2017 Jun 26;12(6):e0180078
pubmed: 28650982
East Mediterr Health J. 2017 Oct 30;23(8):559-563
pubmed: 29105047
J Med Virol. 2008 Oct;80(10):1747-8
pubmed: 18712815
J Med Virol. 2014 Aug;86(8):1366-76
pubmed: 24610501
Int J Gynaecol Obstet. 2004 Jun;85(3):240-4
pubmed: 15145258
J Viral Hepat. 2003 Jan;10(1):61-9
pubmed: 12558914
JNMA J Nepal Med Assoc. 2006 Jan-Mar;45(161):182-5
pubmed: 17160094
Hepatobiliary Pancreat Dis Int. 2008 Apr;7(2):161-4
pubmed: 18397851
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
J Viral Hepat. 2003 May;10(3):224-31
pubmed: 12753342
J Assoc Physicians India. 2015 Jan;63(1):28-33
pubmed: 26591124
Contemp Clin Trials. 2015 Nov;45(Pt A):139-45
pubmed: 26343745
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
J Obstet Gynaecol India. 2019 Feb;69(1):31-36
pubmed: 30814807
Eur J Obstet Gynecol Reprod Biol. 2001 Dec 10;100(1):9-15
pubmed: 11728649
Virol J. 2009 Jul 20;6:108
pubmed: 19619291
PLoS One. 2017 Apr 20;12(4):e0175887
pubmed: 28426700
J Med Virol. 2013 Apr;85(4):620-6
pubmed: 23280991
J Obstet Gynaecol India. 2016 Jun;66(3):166-9
pubmed: 27298525
Hepatobiliary Pancreat Dis Int. 2007 Dec;6(6):596-9
pubmed: 18086624
Virology (Auckl). 2014 May 27;5:15-26
pubmed: 25512696
Liver Int. 2008 Nov;28(9):1190-9
pubmed: 18662274
J Pak Med Assoc. 2013 Sep;63(9):1168-71
pubmed: 24601199
Indian J Gastroenterol. 2007 Mar-Apr;26(2):59-63
pubmed: 17558066
Scand J Infect Dis. 2003;35(6-7):401-3
pubmed: 12953953
Am J Trop Med Hyg. 2019 Jul;101(1):230-232
pubmed: 31115307
J Clin Epidemiol. 2012 Sep;65(9):934-9
pubmed: 22742910
Ann Intern Med. 2007 Jul 3;147(1):28-33
pubmed: 17606958
Int J Gynaecol Obstet. 2001 Feb;72(2):103-8
pubmed: 11166742
J Med Virol. 2010 Oct;82(10):1666-8
pubmed: 20827762
J Obstet Gynaecol Res. 2004 Feb;30(1):48-52
pubmed: 14718021
J Coll Physicians Surg Pak. 2014 Feb;24(2):127-30
pubmed: 24491009
J Med Virol. 1994 Mar;42(3):234-6
pubmed: 8006635
Am J Gastroenterol. 2008 Oct;103(10):2495-501
pubmed: 18785952
Indian J Gastroenterol. 2007 Jan-Feb;26(1):6-10
pubmed: 17401226
PLoS One. 2018 Jan 25;13(1):e0191685
pubmed: 29370271
Arch Gynecol Obstet. 2017 Nov;296(5):885-895
pubmed: 28871471
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Hepatology. 2008 Nov;48(5):1577-85
pubmed: 18925633
Liver Int. 2015 Apr;35(4):1334-40
pubmed: 24974734
Hepatology. 2012 Apr;55(4):988-97
pubmed: 22121109
J Obstet Gynaecol Res. 2016 Jul;42(7):789-95
pubmed: 27075039
J Med Virol. 2019 Nov;91(11):1989-1994
pubmed: 31297845
Cytokine. 2014 Jan;65(1):95-104
pubmed: 24416783
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Virol J. 2014 Apr 09;11:68
pubmed: 24716485
Transfus Clin Biol. 2017 Sep;24(3):176-181
pubmed: 28690036
J Med Virol. 2005 Apr;75(4):499-503
pubmed: 15714491
Fam Med. 2005 May;37(5):360-3
pubmed: 15883903
Can Fam Physician. 2015 Jul;61(7):607-8
pubmed: 26175368
Turk J Obstet Gynecol. 2017 Jun;14(2):106-113
pubmed: 28913146
Expert Opin Pharmacother. 2009 Dec;10(17):2801-9
pubmed: 19929703
Indian J Med Microbiol. 2003 Jul-Sep;21(3):184-5
pubmed: 17643015
J Med Virol. 2015 Mar;87(3):446-50
pubmed: 25164987
Int J Crit Illn Inj Sci. 2013 Jul;3(3):175-82
pubmed: 24404454
PLoS One. 2018 Jan 12;13(1):e0191090
pubmed: 29329329
Trop Med Int Health. 2016 Jan;21(1):108-113
pubmed: 26523476
Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):
pubmed: 29530946
J Epidemiol Community Health. 2013 Nov 1;67(11):974-8
pubmed: 23963506
Hepatol Res. 2013 Aug;43(8):826-35
pubmed: 23279190
Braz J Infect Dis. 2015 Nov-Dec;19(6):672-4
pubmed: 26450652
Pan Afr Med J. 2014 Dec 18;19:391
pubmed: 25995787
Braz J Infect Dis. 2013 Nov-Dec;17(6):716-7
pubmed: 24055390